Our newest product is DOAC Stop; a vital tool for any lab troubled by the new or direct oral anticoagulants. DOAC Stop removes all DOACs from sample plasmas without affecting other tests of haemostasis. Its effect is best measured using our uniformly-sensitive RVV-based DOAC-Test reagent and it complements our HEP-Stop (HRRS) for investigating unexpectedly prolonged APTT results. For lupus anticoagulant testing we have liquid stable dRVT-LS (LA Sensitive) and dRVT-LR (LA Resistant) reagents with "LS/LR" ratios being unaffected by VKA (Warfarin) or DOACs. There is also SACT II, a non-settling alternative to the classic kaolin clotting time (KCT) reagent and the Intrinsin APTT reagents; LA Sensitive and LA-Resistant. All these can be supplied ready for use or as powders for your own reconstitution. Our factor Xa- activated clotting time (XACT) test kit detects procoagulant phospholipids such as those on microparticles and activated platelets. We can supply synthetic phospholipid blends and also other procoagulant products such as soluble ellagic acid and equine collagen.

DOAC-Stop

mini-tablets

 

DOAC-Stop removes all types of Direct Oral Anti-Coagulants (DOACs; dabigatran, apixaban, rivaroxaban, and edoxaban, etc) from test plasmas with minimal effect on underlying blood clotting tests. Just add one mini-tablet per 1ml test plasma (volume is not critical), mix for 5 minutes and centrifuge down the adsorbent. The resulting plasma is then depleted of DOACs and yields similar APTT, dRVVT , PT(INR) and other results as if DOACs had not been present.

Reversing agents coming into therapeutic use for individual DOACs are not widely available for lab tests. DOAC-Stop is now offered for simplifying the diagnostic problems associated with DOACs. It absorbs up to an estimated 2,000ng/ml of any DOAC in less than 5 minutes. Unlike therapeutic additives for reversing DOACs it leaves no residual effect. It can be used for checking if DOACs are present in samples giving unexpectedly prolonged clotting test or abnormal chromogenic test results. There is negligible interference with vitamin K antagonist or heparinoid anticoagulants. Plasmas treated with DOAC-Stop can be used for valid factor assays and in testing for thrombotic risk. In particular it can prevent false LAC positive results due to DOACs or other agents in testing for lupus anticoagulants. Currently RUO. Patent pending.

Please contact Haematex Research (haematex@tpg.com.au) for more information.